Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial.
Pedrosa M, Seyedkazemi S, Francque S, Sanyal A, Rinella M, Charlton M, Loomba R, Ratziu V, Kochuparampil J, Fischer L, Vaidyanathan S, Anstee QM. Pedrosa M, et al. Among authors: kochuparampil j. Contemp Clin Trials. 2020 Jan;88:105889. doi: 10.1016/j.cct.2019.105889. Epub 2019 Nov 13. Contemp Clin Trials. 2020. PMID: 31731005
Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study.
Anstee QM, Lucas KJ, Francque S, Abdelmalek MF, Sanyal AJ, Ratziu V, Gadano AC, Rinella M, Charlton M, Loomba R, Mena E, Schattenberg JM, Noureddin M, Lazas D, Goh GBB, Sarin SK, Yilmaz Y, Martic M, Stringer R, Kochuparampil J, Chen L, Rodriguez-Araujo G, Chng E, Naoumov NV, Brass C, Pedrosa MC. Anstee QM, et al. Among authors: kochuparampil j. Hepatology. 2023 Oct 1;78(4):1223-1239. doi: 10.1097/HEP.0000000000000439. Epub 2023 May 11. Hepatology. 2023. PMID: 37162151 Free PMC article. Clinical Trial.
Efficacy and safety of everolimus with reduced tacrolimus in living-donor liver transplant recipients: 12-month results of a randomized multicenter study.
Jeng LB, Lee SG, Soin AS, Lee WC, Suh KS, Joo DJ, Uemoto S, Joh J, Yoshizumi T, Yang HR, Song GW, Lopez P, Kochuparampil J, Sips C, Kaneko S, Levy G. Jeng LB, et al. Among authors: kochuparampil j. Am J Transplant. 2018 Jun;18(6):1435-1446. doi: 10.1111/ajt.14623. Epub 2018 Jan 25. Am J Transplant. 2018. PMID: 29237235 Free article. Clinical Trial.
Early Conversion From Calcineurin Inhibitor- to Everolimus-Based Therapy Following Kidney Transplantation: Results of the Randomized ELEVATE Trial.
de Fijter JW, Holdaas H, Øyen O, Sanders JS, Sundar S, Bemelman FJ, Sommerer C, Pascual J, Avihingsanon Y, Pongskul C, Oppenheimer F, Toselli L, Russ G, Wang Z, Lopez P, Kochuparampil J, Cruzado JM, van der Giet M; ELEVATE Study Group. de Fijter JW, et al. Among authors: kochuparampil j. Am J Transplant. 2017 Jul;17(7):1853-1867. doi: 10.1111/ajt.14186. Epub 2017 Feb 14. Am J Transplant. 2017. PMID: 28027625 Free article. Clinical Trial.
Cardiovascular Parameters to 2 years After Kidney Transplantation Following Early Switch to Everolimus Without Calcineurin Inhibitor Therapy: An Analysis of the Randomized ELEVATE Study.
Holdaas H, de Fijter JW, Cruzado JM, Massari P, Nashan B, Kanellis J, Witzke O, Gutierrez-Dalmau A, Turkmen A, Wang Z, Lopez P, Bernhardt P, Kochuparampil J, van der Giet M, Murbraech K; ELEVATE Study Group. Holdaas H, et al. Among authors: kochuparampil j. Transplantation. 2017 Oct;101(10):2612-2620. doi: 10.1097/TP.0000000000001739. Transplantation. 2017. PMID: 28333860 Clinical Trial.